News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FDA Grants Orphan Drug Designation to 4SC AG (VSC.DU)'s Oral Pan-HDAC Inhibitor Resminostat for the Treatment of Hepatocellular Carcinoma



7/12/2011 9:47:27 AM

PLANEGG-MARTINSRIED, Germany--(BUSINESS WIRE)--4SC AG (FWB:VSC), a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to 4SC's lead oncology compound resminostat for the treatment of hepatocellular cancer (HCC), the most common form of liver cancer. Resminostat is in Phase II clinical development in advanced HCC, with results expected towards the end of 2011.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES